24/7 Market News Snapshot 18 Dec, 2023 – Invivyd Inc. (NYSE: IVVD)

December 18, 2023

DENVER, Colo., 18 Dec, 2023 (247marketnews.com) – FOR IMMEDIATE RELEASE Leading Financial Institution Announces Exciting…

DENVER, Colo., 18 Dec, 2023 (247marketnews.com) – FOR IMMEDIATE RELEASE

Leading Financial Institution Announces Exciting Price Movement and Biopharmaceutical Company Unveils Positive Clinical Trial Results

A prominent financial institution known for its exceptional financial services, is thrilled to announce a significant price movement in Invivyd Inc. (NYSE:IVVD). The stock price has touched a price of $2.20 representing a monumental 35% percent increase. This extraordinary surge has generated a surge of excitement among investors, with the trading volume reaching an incredible 103776. Investors are eagerly awaiting further updates on this thrilling development.

In other news, Invivyd, Inc., a leading biopharmaceutical company committed to protecting individuals from serious viral infections, has released encouraging preliminary findings from the Phase 3 clinical trial of VYD222. This groundbreaking monoclonal antibody candidate has shown promising efficacy in preventing symptomatic COVID-19.

The CANOPY trial evaluated VYD222 as a preventive measure against the devastating effects of COVID-19. The initial results are highly promising, positioning VYD222 as a potential game-changer in the fight against future viral infections. By targeting a wide range of strains and offering extended protection to vulnerable populations, VYD222 has displayed remarkable efficacy.

“We are delighted to share these compelling preliminary results from our CANOPY trial,” said Dr. Amanda Jones, CEO of Invivyd, Inc. “VYD222 has the potential to make a significant impact on global health, and we are excited to continue its development.”

The positive results indicate that VYD222 effectively reduces the risk of developing symptomatic COVID-19 among participants, underscoring its role as a potent preventive therapy. The trial included a diverse population and adhered to rigorous safety protocols, ensuring the reliable assessment of VYD222’s efficacy and safety.

Invivyd, Inc. remains committed to advancing the CANOPY trial and its collaboration with regulatory authorities for expedited approval of VYD222. The company plans to disclose comprehensive data from the Phase 3 trial soon, including additional analyses on the effectiveness of VYD222 in different age groups and its potential to combat emerging COVID-19 variants.

“Our mission is to protect the vulnerable from serious viral infections, and these promising initial results bring us one step closer to achieving that goal,” added Dr. Jones. “We are committed to the continued development of VYD222 and utilizing the latest advancements in biotechnology to safeguard global communities.”

Connect with 24/7 Market News:
247marketnews.com

https://www.facebook.com/247MarketNewsHQ/

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community.

DISCLAIMER:
24/7 Market News (24/7MN) is a third-party publisher and online news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on the NYSE, NASDAQ, and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7 MN is not affiliated with any company written about in this release and owns no shares of stock. 24/7MN’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.
The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and based on publicly available information which is believed to be reliable.
The stocks and strategies discussed are simply ideas only and are in no way financial advice or recommendations. The author may or may not at any time be holding securities discussed. The author may or may not enter trades in the stocks mentioned. Some positions in mentioned stocks may already be held or are being adjusted or are simply examples, ideas or discussion topics. You are always trading at your own risk.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (IVVD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.